Trial Profile
Phase II Nonrandomized Study of LY353381-HC1 [arzoxifene] in Patients With Recurrent or Advanced Endometrial Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Arzoxifene (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 17 Sep 2005 New trial record.